Chronic Pain Clinical Trial
Official title:
Perioperative Dexamethasone to Promote Systemic Pro-Resolution Phenotype for Prevention of Acute and Chronic Pain Post-Total Knee Arthroplasty.
The purpose of the study is three fold. First to determine the ideal dose of dexamethasone intraoperatively that will reduce acute pain and opioid consumption. Second determine if dexamethasone at the time of surgery reduces chronic pain following total knee arthroplasty and finally determine if a pro-inflammatory environment makes patients susceptible to chronic pain after surgery and can dexamethasone alter this environment. Patients undergoing total knee arthroplasty will be randomized to four groups ( 0mg, 6mg, 12mg and 24mg dexamethasone) and assessments will be made of acute and chronic pain and quality of life measures. Blood samples will be drawn to assess Interleukin levels and for Macrophage sorting. For the primary efficacy endpoint of reduction of opioid consumption over 24 hours after surgery the dexamethasone regimen group will be compared to standard of care group using t-test. For comparisons of the secondary efficacy endpoints, t-test, Chi-square test and Fisher's Exact test will be used. Risks of this study include the risks of venipuncture and intravenous dexamethasone administration.
This is a Phase IV single center, prospective, randomized, double-blind, dose response study
designed to evaluate the optimum dose of dexamethasone to administer as an analgesic in total
knee arthroplasty surgery. Randomization will be performed using computer software and the
randomization order will be written and enclosed in envelopes in the study office. A total of
40 patients will be randomized to receive different doses of dexamethasone intravenously at
induction of anesthesia with the same dose repeated 24 hours later. The dose groups are: 0mg,
6mg, 12mg, 24mg. The groups will be evenly divided into 10 subjects in each group. Patients
will be cared for using established standard of care anesthetic and multi modal analgesia
pathway used clinically at Duke University Medical Center. Knee arthroplasty generally occurs
in patients over 65 years of age and an inclusion criteria is age 55 years or older is
included in the study. Regional anesthesia is more technically challenging in morbidly obese
patients. Because of an increased failure rate of regional anesthesia in morbidly obese
patients an upper limit BMI of 40 is included in the study design.
Anesthetic regime. The anesthesia will be standard of care apart from the administration of
the study drug.
Study Drug. After randomization the first dose of intravenous dexamethasone will be
administered by the anesthesia care team immediately before surgery. The subject and study
personnel will be blinded to the dose. The patient will be sedated and the study personnel
will not be in the operating room. The dose will be recorded on the anesthesia record.
The second dose of dexamethasone will be prescribed by the PI. This will be prescribed
electronically to be administered to the subject on the floor 24 hours after the first dose.
Surgery The surgery will proceed normally with no difference for the study.
Postoperative Pain Management Patients in all groups will receive standard of care
postoperative analgesic regimen.
Blood Samples Blood will be drawn in preop holding (Time 0) for Interleukin 6, Interleukin10
and for macrophage sorting.
Blood samples will be repeated for Interleukin 6 and Interleukin10 at 10-14, 22-26 and
33-39hours after surgery.
Blood samples for macrophage sorting will be repeated at 33-39hours. The total blood
collected will be 30ml on the day of surgery and 10 ml post operative day 1 for an overall
total of 40cc.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01659073 -
Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation
|
N/A | |
Recruiting |
NCT05914311 -
Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration
|
N/A | |
Recruiting |
NCT05422456 -
The Turkish Version of Functional Disability Inventory
|
||
Enrolling by invitation |
NCT05422443 -
The Turkish Version of Pain Coping Questionnaire
|
||
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04385030 -
Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury
|
N/A | |
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05103319 -
Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
|
||
Completed |
NCT03687762 -
Back on Track to Healthy Living Study
|
N/A | |
Completed |
NCT04171336 -
Animal-assisted Therapy for Children and Adolescents With Chronic Pain
|
N/A | |
Completed |
NCT03179475 -
Targin® for Chronic Pain Management in Patients With Spinal Cord Injury
|
Phase 4 | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Recruiting |
NCT06060028 -
The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain
|
N/A | |
Recruiting |
NCT06204627 -
TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain
|
N/A | |
Completed |
NCT05496205 -
A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT00983385 -
Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics
|
Phase 3 | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Terminated |
NCT03538444 -
Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder
|
N/A | |
Not yet recruiting |
NCT05812703 -
Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain
|